Case of plasmablastic lymphoma of the sigmoid colon and literature review

Author(s)
Haramura, Tomoko; Haraguchi, Masashi; Irie, Junji; Ito, Shinichiro; Tokai, Hirotaka; Noda, Kazumasa; Kitajima, Masachika; Minami, Shigeki; Inoue, Keiji; Sasaki, Yuya; Oshima, Koichi; Eguchi, Susumu

Citation

Issue Date
2015-06-28

URL
http://hdl.handle.net/10069/35726

Right
©2015 Baishideng Publishing Group Inc. All rights reserved. Articles published by this open-access journal are distributed under the terms of the Creative Commons Attribution-Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

NAOSITE: Nagasaki University's Academic Output SITE
http://naosite.lb.nagasaki-u.ac.jp
Case of plasmablastic lymphoma of the sigmoid colon and literature review

Tomoko Haramura, Masashi Haraguchi, Junji Irie, Shinichiro Ito, Hirotaka Tokai, Kazumasa Noda, Masachika Kitajima, Shigeki Minami, Keiji Inoue, Yuya Sasaki, Koichi Oshima, Susumu Eguchi

Tomoko Haramura, Masashi Haraguchi, Shinichiro Ito, Hirotaka Tokai, Kazumasa Noda, Masachika Kitajima, Shigeki Minami, Keiji Inoue, Department of Surgery, Nagasaki Harbor Medical Center City Hospital, Nagasaki 850-8555, Japan

Junji Irie, Department of Pathology, Nagasaki Harbor Medical Center City Hospital, Nagasaki 850-8555, Japan

Yuya Sasaki, Koichi Oshima, Department of Pathology, Kurume University, Fukuoka 830-0011, Japan

Susumu Eguchi, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan

Author contributions: Haraguchi M wrote the manuscript and organized the figures; Haramura T and Eguchi S assisted in writing the manuscript; Ito S, Tokai H, Noda K, Kitajima M, Minami S and Inoue K attended the patient; Irie J, Sasaki Y and Oshima K performed the pathological examination and provided the slides.

Conflict-of-interest: None of the authors have a conflict of interest related to the manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Revised: January 29, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: June 28, 2015

Abstract

Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin’s lymphoma that is associated with human immunodeficiency virus (HIV) infection. Although PBL is most commonly observed in the oral cavity of HIV-positive patients, it can also be observed at extra-oral sites in HIV-negative patients. This report represents an unusual case of HIV-negative PBL that occurred in the sigmoid colon. This patient had a history of systemic lupus erythematosus and an underlying immunosuppressive state from long term steroid therapy. The lymphoma cells were positive for CD138, kappa light chain restriction and Epstein-Barr virus and negative for CD20/L26, CD3, CD79a, UCHL1 (CD45RO) and cytokeratin (AE1/AE3). The patient died approximately 2 mo after the operation. In the present paper, we review cases of PBL of the colon in HIV-negative patients.

Key words: Plasmablastic lymphoma; Sigmoid colon; Human immunodeficiency virus-negative; Immunosuppressive state; Extra-oral site

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin’s lymphoma that is associated with human immunodeficiency virus (HIV) infection. Although PBL is most commonly observed in the oral cavity of HIV-positive patients, it can also be observed at extra-oral sites in HIV-negative patients with an underlying immunosuppressive state. The gastrointestinal tract and skin are the most commonly involved extra-oral organ systems and cases...
considered as a diffuse large-B-cell non-Hodgkin's lymphoma variant, plasmablastic lymphoma (PBL) is an aggressive and rapidly growing lymphoma characterized by weak/absent expression of conventional B-cell markers and by strong expression of plasma cell markers. PBL was described as a new disease entity in the 4th WHO classification\(^1\). PBL was first reported in the oral cavity in the setting of human immunodeficiency virus (HIV) in 1997 by Delecluse et al\(^2\), originally described in 16 cases of a variant of diffuse large B-cell lymphoma (DLBCL). Although PBL is strongly associated with HIV infection, an increasing number of cases have recently been recognized in a non-HIV population, as in our case\(^3\). These cases often occur in patients with an underlying immunosuppressive state, such as from solid organ and bone marrow transplantation, and from lymphoproliferative or autoimmune disorders. A characteristic feature of PBL is its rapidly progressive clinical course. However, the overall survival is better in HIV-positive patients treated with highly active antiretroviral therapy (HAART) and appropriate chemotherapy than in HIV-negative patients\(^4\).

Several reports have described the occurrence of PBL in extra-oral sites, including the skin, stomach, small intestine, anal mucosa or perianal area, lung, liver, retroperitoneum and other regions\(^5\)-\(^10\).

We describe a case of PBL of the sigmoid colon in a HIV-negative but Epstein-Barr virus (EBV)-positive patient who presented with gastrointestinal bleeding.

According to our research, before our case, there have only been four cases of PBL of the colon in an HIV-negative patient. Herein, we review the literature of rare cases of PBL of the colon.

**CASE REPORT**

An 86-year-old female was admitted to our hospital's emergency department because of bloody stool. On physical examination, she had no abdominal pain and no tenderness with guarding or rebound. At presentation, laboratory data revealed the following results: white blood count at 13100 cells/mm\(^2\), hemoglobin at 13.2 mg/dL, C-reactive protein at 2.1 mg/dL, and negative status for hepatitis B and C and for human T-cell lymphotropic virus 1. The patient was known to have systemic lupus erythematosus (SLE) and type 2 diabetes mellitus. The patient was receiving steroidal treatment for SLE. A computed tomography scan of her abdomen revealed a mass measuring 5 cm in diameter, multiple diverticula in the sigmoid colon and enlarged lymph nodes in the sigmoid mesentery (Figure 1). Free air was not detected in the abdominal cavity. Colonoscopy was performed and a tumor with bleeding in the sigmoid colon was revealed. Because bleeding due to sigmoid colon cancer was suspected, sigmoidectomy with Hartmann's procedure was urgently performed. The excised material revealed the tumor to be tender, 5 cm × 4.5 cm in size, and displaying the diverticulosis (Figure 2A). On the cut surface, the tumor was soft, consistent with hemorrhage (Figure 2B). Microscopically, the tumor cells had large hyperchromatic nuclei with prominent

---

**Figure 1** Computed tomography of abdomen. Computed tomography scan showed a mass measuring 5 cm in diameter, multiple diverticula in the sigmoid colon and enlarged lymph nodes in the sigmoid mesentery.

**Figure 2** Gross appearance of the primary tumor lesion. A: A tumor (5 cm in diameter) is present in the sigmoid colon. Coagulation is on the surface; B: The tumor showed hemorrhage on the surface and a white mass within and was soft in consistency.
nucleoli. Some tumor cells showed plasmacytic differentiation (hematoxylin and eosin (HE) staining, original magnification × 400); B: The atypical cells are negative for the B-cell marker CD20 (original magnification × 400); C: The atypical cells are diffusely positive for the plasma cell marker CD138 (original magnification × 400); D: The nuclei of the atypical cells are positive for EBER, which is Epstein-Barr encoded RNA (original magnification × 400); E: The atypical cells are negative for the leukocyte common antigen CD45RO (UCHL1) (original magnification × 400); F: The atypical cells are negative for the T-cell marker CD3 (original magnification × 400); G: The atypical cells are negative for the pan-B-cell marker CD79a (original magnification × 400).

Figure 3 Plasmablastic lymphoma of the sigmoid colon. A: Tumor cells have large hyperchromatic nuclei with prominent nucleoli. Some tumor cells showed plasmacytic differentiation (hematoxylin and eosin (HE) staining, original magnification × 400); B: The atypical cells are negative for the B-cell marker CD20 (original magnification × 400); C: The atypical cells are diffusely positive for the plasma cell marker CD138 (original magnification × 400); D: The nuclei of the atypical cells are positive for EBER, which is Epstein-Barr encoded RNA (original magnification × 400); E: The atypical cells are negative for the leukocyte common antigen CD45RO (UCHL1) (original magnification × 400); F: The atypical cells are negative for the T-cell marker CD3 (original magnification × 400); G: The atypical cells are negative for the pan-B-cell marker CD79a (original magnification × 400).

Nucleoli. Some tumor cells showed plasmacytic differentiation (Figure 3A). There was no epithelial component. Therefore, malignant lymphoma or diffuse lymphoma was suspected. Immunohistochemical examination revealed that the tumor cells were negative for CD20/L26 (Figure
EBV (Figure 3D). The patient’s light chain restriction and EBV (Figure 3C), kappa CD3, CD79a, UCHL1 (CD45RO) and cytokeratin (AE1/AE3), but positive for CD138 (Figure 3C), kappa light chain restriction and EBV (Figure 3D). The patient’s HIV negative status was proven after the surgery. Based on these results, our final diagnosis was PBL. The patient continued to deteriorate clinically and developed multiorgan failure. The patient died approximately 2 mo after surgery after refusing chemotherapy and radiotherapy. Autopsy was not performed.

**DISCUSSION**

PBL has been recognized as a distinct entity, a subtype of diffuse large B-cell lymphoma, by the WHO classification of lymphoproliferative disorders.[11] PBL accounts for 1.5% of nodal non-Hodgkin’s lymphomas and has a strong predilection for immunodeficiency, particularly HIV. In patients with PBL in HIV infection, the median age was 38 years with a male predominance of 7:1. The prognosis remains poorer than that of other DLBCL.[12] The risk of developing non-Hodgkin’s lymphoma is 200 times higher in HIV-positive patients than in otherwise healthy persons. However, an increasing number of PBL cases have recently been recognized in patients without HIV infection. In HIV-negative individuals, PBL cases have been reported after solid organ transplantation, in association with steroid therapy for autoimmune disease, and some other types of immunosuppression.[13,14] About one-third of PBL-diagnosed HIV negative patients have presented with an underlying immunosuppressive state.[15] The present patient had a diagnosis of SLE and a history of steroidal treatment for 35 years before developing lymphoma. This steroidal therapy probably led to the iatrogenic immunocompromised state. There was no family history of any hematological malignancies. Except for the steroidal therapy, our patient had never received any other treatment which could lead to an iatrogenic immunocompromised state.

The present case is HIV-negative but EBV-positive. EBV plays an important role in the tumorigenesis of HIV-associated PBL.[16] HIV infection creates a favorable environment for chronic EBV infection, with a subsequent latency that predisposes EBV-transformed B-cells to become malignant. It has been reported that EBV infection was detected in 72% of PBL cases.[17] However, EBV infection has been detected in only 17% of HIV-negative PBL cases, which suggests that PBL pathogenesis is not specific to EBV infection.[5]

The histological appearance of PBL is usually monomorphic with a diffuse lymphoid infiltrate and cohesive growth pattern.[18] The main differential diagnosis of PBL includes other forms of DLBCL, plasmacytoma/myeloma, Burkitt’s lymphomas, poorly differentiated carcinoma and malignant melanoma; for such a differential diagnosis, the help of morphological characteristics and behavior are often effective.[16]

Unlike PBL, DLBCL always expresses CD20, CD45-RA and CD79a. Plasmacytoma typically consists of mature plasma cells without a high rate of mitotic activity. Burkitt’s lymphomas express a membrane-bound IgM heavy chain isotype. PBL expresses immunoreactivity for plasma cell markers (CD38, CD138) and is weakly positive or negative for CD45 and CD20. CD79a is positive in approximately 50%-85% of all PBL cases.[16] CD138 is a highly specific and sensitive marker of plasmacytic differentiation within the spectrum of hematological malignancy. CD138 reactivity has been reported with variable frequency in immunoblastic diffuse large B-cell lymphoma. CD56 and cyclin D1 are usually negative. However, a differential diagnosis between PBL and plasmacytoma is difficult without histological examination.

The most notable feature of PBL is its predilection for the oral cavity. Most patients with PBL present with a primary oral lesion, often complaining of a toothache or tooth abscess.[19] PBL can be observed at extra-oral sites in HIV-negative patients. As for extra-oral organ systems, the gastrointestinal tract and skin are the most commonly involved[19] but only four PBL cases of the colon in HIV-negative patients have been reported before our case.[4,20,21] (Table 1).

The general prognosis of PBL is very poor, with a rapidly progressive clinical course[19]. However, clinicopathological characteristics of PBL patients differ between HIV-positive and HIV-negative status, where HIV-positive patients have better response to chemotherapy and longer survival[5]. For HIV-positive PBL patients, recent reports have noted improved survival when treating with both HAART and appropriate chemotherapy, such as cyclophosphamide,

**Table 1 Patient clinical, tumor, immunohistochemical and Epstein-Barr virus status characteristics**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Gender</th>
<th>Primary site</th>
<th>CD3</th>
<th>CD20</th>
<th>CD45</th>
<th>CD79a</th>
<th>CD138</th>
<th>EBV</th>
<th>Cyclin D1</th>
<th>CD56</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>56</td>
<td>M</td>
<td>Sigmoid</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2&lt;sup&gt;1&lt;/sup&gt;</td>
<td>29</td>
<td>M</td>
<td>Colon</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3</td>
<td>75</td>
<td>M</td>
<td>Cecum</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>77</td>
<td>F</td>
<td>Cecum</td>
<td>-</td>
<td>-</td>
<td>ND</td>
<td>+/-</td>
<td>-</td>
<td>ND</td>
<td>-</td>
<td>ND</td>
</tr>
<tr>
<td>5&lt;sup&gt;2&lt;/sup&gt;</td>
<td>86</td>
<td>F</td>
<td>Sigmoid</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

<sup>1</sup>Patient with history of ulcerative colitis; <sup>2</sup>Present patient. M: Male; F: Female; ND: Not determined; CD3: T-cell marker; CD20: B-cell marker; CD45: Leukocyte common antigen; CD79a: Pan-B-cell marker; CD138: Plasma cell marker; EBV: Epstein-Barr virus; Cyclin D1: Mantle cell lymphoma marker; CD56: NK-cell marker.
doxorubicin, vincristine and prednisone, with similar outcomes for HIV-infected patients to other non-Hodgkin’s lymphomas\(^\text{19}\). Several patients have been documented to have survived for more than 3 years from the time of initial diagnosis of PBL, usually with a combination of HAART plus chemotherapy\(^\text{19}\).

Extra-oral PBL can often occur in HIV-negative patients and is highly aggressive, with a poor prognosis. Although identifying extra-oral PBL requires familiarity with lymphoma variants and related differential diagnosis procedures, PBL should be suspected if the patient is immunosuppressed. A high index of suspicion by the clinician and pathologist might lead to initiating appropriate treatments and account for better outcomes.

**REFERENCES**


Haramura T et al. Plasmablastic lymphoma of the sigmoid colon


P- Reviewer: Humanci O, Yao HR   S- Editor: Ma YJ
L- Editor: Roemmele A   E- Editor: Zhang DN